/DYAI
DYAI Stock - Dyadic International, Inc.
Healthcare|BiotechnologyNASDAQ
$1.00+9.89%
+$0.09 (+9.89%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.42
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+200.1%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DYAI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.99 – $1.01
TARGET (TP)$3.00
STOP LOSS$0.92
RISK/REWARD1:25.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.23
52W High$2.14
52W Low$0.71
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.50M | $2.90M | $2.93M | $2.40M | $1.60M |
| Gross Profit | $2.30M | $922,957 | $807,110 | $459,393 | $176,990 |
| Gross Margin | 65.8% | 31.8% | 27.5% | 19.1% | 11.0% |
| Operating Income | $-5,900,822 | $-8,229,739 | $-10,165,678 | $-14,727,487 | $-10,025,663 |
| Net Income | $-5,809,159 | $-6,795,461 | $-9,735,258 | $-13,070,251 | $-9,325,273 |
| Net Margin | -166.2% | -234.4% | -332.2% | -543.7% | -582.1% |
| EPS | $-0.20 | $-0.24 | $-0.34 | $-0.47 | $-0.34 |
Company Overview
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$3
Average Target
↑ 200.1% Upside
Now
$3
Low
$3
Average
$3
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 23rd 2025 | H.C. Wainwright | Resumed | Buy | $3 |
| September 8th 2025 | Craig Hallum | Initiation | Buy | - |
| July 18th 2022 | Dawson James | Downgrade | Neutral | - |
Earnings History & Surprises
DYAIBeat Rate
19%
Last 16 quarters
Avg Surprise
-49.1%
EPS vs Estimate
Beats / Misses
3/8
5 met exactly
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q1 24
-14.3%
$-0.08vs$-0.07
Q2 24
No data
Q3 24
0.0%
$-0.07vs$-0.07
Q4 24
+85.7%
$-0.01vs$-0.07
Q1 25
-25.0%
$-0.05vs$-0.04
Q2 25
No data
Q3 25
0.0%
$-0.06vs$-0.06
Q4 25
-50.0%
$-0.06vs$-0.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $-0.03 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.04 | $-0.06 | -50.0% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.06 | $-0.06 | 0.0% | = MET |
Q2 2025 | May 14, 2025 | — | $-0.07 | — | — |
Q1 2025 | Mar 26, 2025 | $-0.04 | $-0.05 | -25.0% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.07 | $-0.01 | +85.7% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.07 | $-0.07 | 0.0% | = MET |
Q2 2024 | May 14, 2024 | — | $-0.07 | — | — |
Q1 2024 | Mar 28, 2024 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.06 | $-0.06 | 0.0% | = MET |
Q3 2023 | Aug 9, 2023 | $-0.05 | $-0.07 | -40.0% | ✗ MISS |
Q2 2023 | May 10, 2023 | — | $-0.03 | — | — |
Q1 2023 | Mar 29, 2023 | $-0.07 | $-0.07 | 0.0% | = MET |
Q4 2022 | Nov 10, 2022 | $-0.10 | $-0.06 | +40.0% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.09 | $-0.12 | -33.3% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.09 | $-0.09 | 0.0% | = MET |
Q1 2022 | Mar 29, 2022 | $-0.03 | $-0.15 | -500.0% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.10 | $-0.06 | +40.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.09 | $-0.14 | -55.6% | ✗ MISS |
Q2 2021 | May 13, 2021 | $0.09 | $-0.12 | -233.3% | ✗ MISS |
Latest News
Dyadic Applied BioSolutions Expands Collaboration With Fermbox Bio To Manufacture And Commercialize Animal-Free Proteins And Enzymes
📈 PositiveBenzinga•Dec 17, 2025, 12:23 PM
Dyadic Applied Biosolutions Announced A Commercial Agreement With Opes Diagnostics To Support The Commercial Launch Of Dyadic's Recombinant Human Transferrin, Bovine Transferrin, Human FGF, And Bovine FGF Products For Use In Serum-free Cell Culture Media Applications
📈 PositiveBenzinga•Dec 15, 2025, 12:26 PM
DYAI stock has given up its prior gain. Dyadic International shares were trading higher after the company announced it signed a Development and Commercialization Agreement with BRIG Bio to jointly develop and commercialize recombinant bovine alpha-lactalbumin.
➖ NeutralBenzinga•Dec 1, 2025, 04:04 PM
Dyadic International shares are trading higher after the company announced it signed a Development and Commercialization Agreement with BRIG Bio to jointly develop and commercialize recombinant bovine alpha-lactalbumin.
📈 PositiveBenzinga•Dec 1, 2025, 02:27 PM
Market-Moving News for December 1st
➖ NeutralBenzinga•Dec 1, 2025, 12:37 PM•Also: ,
Dyadic Applied BioSolutions And BRIG BIO Signs Development And Commercialization Agreement To Jointly Develop And Commercialize Recombinant Bovine Alpha-Lactalbumin
📈 PositiveBenzinga•Dec 1, 2025, 12:30 PM
Dyadic International Q3 EPS $(0.06) Misses $(0.04) Estimate, Sales $1.165M Beat $1.100M Estimate
➖ NeutralBenzinga•Nov 12, 2025, 09:06 PM
Dyadic Applied BioSolutions, ERS Genomics Signs Agreement To Grant Dyadic Access To ERS' CRISPR/Cas9 Patent Portfolio
📈 PositiveBenzinga•Nov 10, 2025, 12:28 PM
HC Wainwright & Co. Assumes Dyadic International at Buy, Announces Price Target of $3
📈 PositiveBenzinga•Oct 23, 2025, 10:41 AM
Dyadic International Narrows Q2 Loss
📈 PositiveThe Motley Fool•Aug 13, 2025, 10:15 PM
Dyadic Revenue Jumps 150% in Fiscal Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 09:52 PM
Frequently Asked Questions about DYAI
What is DYAI's current stock price?
Dyadic International, Inc. (DYAI) is currently trading at $1.00 per share. The stock has moved +9.89% today.
What is the analyst price target for DYAI?
The average analyst price target for DYAI is $3.00, based on 1 analyst.
What sector is Dyadic International, Inc. in?
Dyadic International, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DYAI's market cap?
Dyadic International, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does DYAI pay dividends?
No, Dyadic International, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
ATHE
Alterity Therapeutics Limited
$3.09
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
ELUT
Elutia Inc.
$0.59
Mkt Cap: $0.0B
MAIA
MAIA Biotechnology, Inc.
$1.22
Mkt Cap: $0.0B
PYPD
PolyPid Ltd.
$3.97
Mkt Cap: $0.0B
RNXT
RenovoRx, Inc.
$0.93
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
VERU
Veru Inc.
$2.32
Mkt Cap: $0.0B
Explore stocks similar to DYAI for comparison